Trials / Terminated
TerminatedNCT05336409
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Century Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CNTY-101 | CNTY-101 cells for intravenous (IV) infusion |
| BIOLOGICAL | IL-2 | IL-2 subcutaneous (SQ) injection |
| DRUG | Lymphodepleting Chemotherapy | LDC as prespecified in the protocol. |
Timeline
- Start date
- 2023-01-24
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2022-04-20
- Last updated
- 2025-12-18
Locations
16 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05336409. Inclusion in this directory is not an endorsement.